HemoShear Therapeutics

62 articles with HemoShear Therapeutics

• HemoShear Therapeutics to Participate in Piper Sandler Healthcare Conference

  11/17/2022

  HemoShear Therapeutics, Inc. will present at the 34th Annual Piper Sandler Healthcare Conference being held November 29 – December 1 in New York City.

• HemoShear Therapeutics to Participate in SVB Leerink Securities Biopharma Private Company Connect

  10/18/2022

  HemoShear Therapeutics, Inc. today announced that it will participate in SVB Leerink Biopharma Private Company Connect being held virtually October 26-27.

• HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline

  9/21/2022

  HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP).

• HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

  8/25/2022

  HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff , PhD, as interim chief executive officer.

• HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda

  8/10/2022

  HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda.

• HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

  12/14/2021

  HemoShear Therapeutics, Inc. has appointed Patrick Horn , MD, PhD, as Chief Medical Officer, effective January 1, 2022.

• HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda

  11/16/2021

  HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company's REVEAL-Tx ™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited

• HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

  9/21/2021

  HemoShear Therapeutics, Inc. has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc

• HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

  7/22/2021

   HemoShear Therapeutics, Inc. today announced that the first two patients have been dosed in the HERO Phase 2 clinical trial of HST5040.

• 

  Horizon Bets $700 Million on Arrowhead's Gout RNAi Drug

  6/21/2021

  Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine. 

• HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

  4/21/2021

    HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc

• Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear's HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

  3/31/2021

  HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism , demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia

• HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

  2/10/2021

  HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, has raised $40 million in a Series A financing.

• HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

  12/10/2020

  HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited ("Takeda") to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda's discovery portfolio.

• HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

  10/21/2020

   HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has entered into a research collaboration and service agreement with Takeda Pharmaceutical Company Limited ("Takeda"). Under the terms of the agreement, H

• HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia

  7/28/2020

  HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for HST5040, a once-daily oral small molecule drug being developed to treat methylmalonic acidemia (MMA) and propionic acidemia (PA).  

• HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

  7/9/2020

   HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear's team has made significant progress and the company will r

• HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

  6/24/2020

   HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a phase 2 clinical trial of HST5040, an oral small molecule drug for the treatment of patients

• HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

  9/25/2019

  HemoShear Therapeutics, LLC, a privately held biotechnology company focused on discovering and developing drugs for metabolic disorders, has appointed Brian A. Johns, PhD, as Chief Scientific Officer

• HemoShear Therapeutics to Present at Wedbush PacGrow Healthcare Conference

  8/6/2019

  HemoShear Therapeutics, LLC, a privately held biotechnology company focused on discovering and developing drugs for metabolic disorders, today announced that Jim Powers, Chairman and CEO, will present at the 2019 Wedbush PacGrow Healthcare Conference